Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | CHIEF SCIENTIFIC OFFICER | January 21, 2026 | January 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date January 21, 2026 · Filed January 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.57 · Expires 2036-01-20 | Direct | 250,000 |
Reported balance
After 2026-01-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-21 · Grant · Acquired 250,000 · Balance 250,000 F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2026 Filed Jan 23, 2026 16:05 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.57 | $0.00 |
DisclosureSEC source: 0001880385-26-000002 · form4-01232026_040106.xml · derivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2036-01-20 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 21, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 16:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001415889-25-002492 · form4-01312025_090123.xml · derivative · entry 2 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2035-01-29 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| January 30, 2025 Filed Jan 31, 2025 16:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002492 · form4-01312025_090123.xml · nonDerivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,192 F1 · kind: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 50% of the RSUs shall vest on January 30, 2026 and the remaining 50% of the RSUs shall vest on January 30, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 14, 2024 Filed Feb 15, 2024 17:36 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001415889-24-003965 · form4-02152024_100219.xml · derivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-02-13 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 14, 2025, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:10 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022386 · tm236831-2_4seq1.xml · derivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:16 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001514 · form4-02172022_010238.xml · derivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.